Structure Search


    Online Support

  •  Customer service

    Location: Industrial Info

The treatment of diabetes may reduce the risk of Parkinson's disease

2017-08-08 来源:转载自第三方
8 August 2017
  Is there a relationship between diabetes and Parkinson's disease? Recent studies have suggested that the relationship between neurological degeneration and diabetes can not be ignored. With the deepening of the study, scientists have found some drugs used to treat diabetes originally, also has a certain effect on Parkinson's disease.
  An important 12-year study shows that diabetes increases the risk of Parkinson's disease by more than 2 times, and the use of sulfonylureas increases by a further 57%, while metformin is used for treatment without increasing the risk of Parkinson's disease. Metformin is not only a first-line medication for diabetes, but also seems to protect the brain from neurodegeneration and reduce the risk of Parkinson's disease.
  A study published in the The Lancet Journal shows that Exenatide, which is commonly used to treat diabetes, may have the potential to improve Parkinson's disease. Exenatide is a GLP-1 receptor agonist and has been approved by the FDA for the treatment of type 2 diabetes in 2006. GLP-1 receptors are also found in the brain, activation of these receptors can enhance the function of dopamine connection, play an anti-inflammatory effect, improve energy generation and open cell survival signal. Previous evidence in animal models also showed that exenatide improved motor performance, and the study further confirmed the effect of exenatide on patients with Parkinson's disease.
Actos, Avandia
  A study shows that diabetes drugs Actos, Avandia and other drugs may protect patients against Parkinson's disease. The generic name of Actos is pioglitazone, and the generic name of Avandia is rosiglitazone. During the study period, patients who were taking Pioglitazone were found to be 28% less likely to be diagnosed with Parkinson's disease than those who did not take the drug.
  A study has found that a drug originally designed for the treatment of diabetes—MSDC-0160, may be a breakthrough for the treatment of Parkinson's disease. MSDC-0160 is an MTOT modulator for regulating mitochondrial function. Initially used to treat type 2 diabetes, it seems to restore the ability of brain cells to convert nutrients into usable energy. In this study, the researchers used the Parkinson mouse model to obtain positive results using MSDC-0160 treatment.
  Diabetes and Parkinson seem to be two completely unrelated diseases, the symptoms are completely different, but there are some similar molecular mechanisms between the two. Over the past few decades, the treatment of Parkinson's disease has made important breakthroughs, and researchers will also continue to investigate the compounds which will affect the development of Parkinson's disease.
Related links: 1,1-metformin hydrochloride

Edited by Suzhou Yacoo Science Co., Ltd. 


Copyright © 2010 SuZhou Yacoo Science Co., Ltd All Rights Reserved Powered by: Founder International
Yacoo Information Management Platform   用户登录   站内地图